Professor of Medicine, Oregon Health and Sci University
Endocrinology
Dr. Matthew C. Riddle Jr., MD
|
|
Give Review
Matthew Riddle is an expert in the field of Endocrinology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACE)". Matthew C. Riddle Jr. has written publications. He has 38 publications published with PubMed. The lastest paper is: 'Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.
- SGLT2 Inhibitors: The Latest "New Kids on the Block"!
- Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differences.
- Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 Diabetes management: reflections from a Diabetes ca...
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in ...
- Reduced risk of hypoglycemia With once-daily glargine versus twice-daily NPH and number needed to harm With NPH to demonstrate the risk of one additional hypoglycemic ...
- Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 Diabetes: twice-daily premixed insulin versus basal insulin with either basal-pl...
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L).
- Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance.
- Contributions of Basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 Diabetes mellitus.
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-Week, Randomized...
- Influence of glucocorticoids and growth hormone on insulin sensitivity in humans.
- Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 Diabetes: a patient-level analysis of 12 studies.
- Clinical Predictors of Risk of Hypoglycaemia During Addition and Titration of Insulin Glargine for Type 2 Diabetes Mellitus.
- Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
- Twenty-four hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects With varying degrees of glucose tolerance following short-term medium-d...
- International forum for the advancement of Diabetes research and care, april 29-30, 2011, athens, Greece.
- EFFECTS OF INITIATION AND TITRATION OF A SINGLE PRE-PRANDIAL DOSE OF INSULIN GLULISINE WHILE CONTINUING TITRATED INSULIN GLARGINE IN TYPE 2 Diabetes: A 6-MONTH 'PROOF-...
- Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
- More reasons to say goodbye to glyburide.
- Effects of intensive glucose lowering in the management of patients with type 2 Diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
- Starting and advancing insulin for type 2 Diabetes: algorithms and individualized methods are both necessary.
- Combined therapy With insulin plus oral agents: is there any advantage? An argument in favor.
- Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine com...
- Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.
- The Treat-to-Target Trial and related studies.
- Making the transition from oral to insulin therapy.
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 Diabetes treated with metformin and a sulfonylurea.
- Glycemic management of type 2 Diabetes: an emerging strategy with oral agents, insulins, and combinations.
- Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 Diabetes.
- Type 2 Diabetes: the role of basal insulin therapy.
- What to do when two oral agents fail to control type 2 Diabetes--a matter of opinion or a matter of fact?
- Timely initiation of basal insulin.
- Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
- Current oral agents for type 2 Diabetes. Many options, but which to choose when?
- Timely addition of insulin to oral therapy for type 2 Diabetes.
- Pramlintide: an agent for glycemic control plus weight control?
Schools
Harvard Medical School
Washington Center School of Medicine
Rush Presby St Lukes Hospital
Rush Presby St Lukes
University of Washington
Procedures Preformed
- Continuous Glucose Monitoring
Conditions Treated
- Diabetes Type 1
- Diabetes Type 2
- Diabetes With Renal Manifestations
- Diabetic Retinopathy
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACE)
Education
-
Rush University Medical Center -
Harvard Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Donald J. Bouma, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyun S. Suh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Lundblad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa A. Hillier, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Joseph S. Mallov, MD
This Doctor is OpenDoctor Recommended.
|